Article Details

Invivyd Announces Dosing of First Participant in CANOPY - GlobeNewswire

Retrieved on: 2023-09-11 11:41:37

Tags for this article:

Click the tags to see associated articles and topics

Invivyd Announces Dosing of First Participant in CANOPY - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2023/09/11/2740638/0/en/Invivyd-Announces-Dosing-of-First-Participant-in-CANOPY-Phase-3-Pivotal-Clinical-Trial-Investigating-VYD222-for-the-Prevention-of-Symptomatic-COVID-19.html

Excerpt

VYD222 is a broadly neutralizing, half-life extended monoclonal antibody (mAb) candidate in development for the prevention of symptomatic COVID-19 ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up